Reference entry · HGF/c-Met pathway mimetic oligopeptide
Dihexa
Also known as: N-hexanoic-Tyr-Ile-Gly-Ser-Phe · HGF mimetic pentapeptide
- Class
- HGF/c-Met pathway mimetic oligopeptide
- Size
- 5 amino acids + N-hexanoic modification
- Primary targets (literature)
- Hepatocyte growth factor / c-Met signaling (preclinical literature)
- Regulatory context
- Not FDA-approved. Catalog dihexa is research-use-only material distinct from any pharmaceutical HGF or c-Met drug product.
Overview
Dihexa is a synthetic oligopeptide developed as a small-molecule mimetic of hepatocyte growth factor signaling. Preclinical literature emphasizes synaptogenesis and cognitive endpoints in rodent models — with no established human clinical program for catalog material.
Mechanism in research literature
Published models propose potentiation of HGF/c-Met pathway activity at low concentrations, influencing dendritic spine formation and synaptic connectivity in brain tissue — mechanistic claims remain concentrated in a narrow investigator network.
Common research focus areas
- Synaptogenesis and memory assays in rodents
- c-Met receptor pharmacology in vitro
- Comparison with CNTF-pathway peptides such as P21
- N-hexanoic modification and sequence identity verification
Full literature roundup
Read the cited research summary
An HGF-mimetic oligopeptide studied for synaptogenesis in rodent cognition models. What the preclinical record reports — and what remains unestablished in humans.
Dihexa research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.